Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0M7QR
|
||||
Former ID |
DNC008261
|
||||
Drug Name |
5-ethyl-2-(2-(pyrrolidin-1-yl)ethyl)pyridine
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C13H20N2
|
||||
Canonical SMILES |
CCC1=CN=C(C=C1)CCN2CCCC2
|
||||
InChI |
1S/C13H20N2/c1-2-12-5-6-13(14-11-12)7-10-15-8-3-4-9-15/h5-6,11H,2-4,7-10H2,1H3
|
||||
InChIKey |
LTRFAPGENZNRNS-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Histamine H3 receptor | Target Info | Inhibitor | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
Reactome | Histamine receptors | ||||
G alpha (i) signalling events | |||||
WikiPathways | Monoamine Transport | ||||
GPCRs, Class A Rhodopsin-like | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. Epub 2007 Oct 24.In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.